Peptides surge in popularity for anti-aging, but a dark gray market poses serious risks. Experts call for oversight. GLP-1 agonists like semaglutide spark a peptide revolution, but unapproved compound...
A March 2025 study in Cell Reports Medicine finds that muscle loss from GLP-1 drugs mirrors ordinary weight loss, alleviating public concern. A new study reassures that GLP-1 drugs do not cause dispro...
GLP-1 receptor agonists, including semaglutide and tirzepatide, reduce cardiovascular risks by 20%, improve kidney function, and aid NAFLD, with microdosing minimizing side effects for better adherenc...